Introduction: The coronavirus disease 2019 (COVID-19) is worldwide outbreak. Globally there are 21,159,730 reported
confirmed cases and there is almost no country in the world that is not affected by COVID-19 (3). It is caused by severe acute
respiratory syndrome coronavirus 2 respiratory syndrome coronavirus 2 (SARS-CoV-2) enter the cells through angiotensin
converting enzyme 2 (ACE2) receptor that act as key regulator of blood pressure.
Objective: To summarize the most updated data on COVID-19 and hypertension.
Methodology: A PubMed and UpToDate search was completed in Clinical Queries using the key terms ‘COVID-19 in hypertension
patients ‘and ‘COVID-19 ‘. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational
studies, and reviews.
Result: 1099 patients with confirmed COVID-19, of which the single highest risk factor of infection was hypertension reported
in 15% of patients. Meta-analysis of six studies (1527) patients, hypertension was present in 17.1% of patients with the infection.
The median age of SARS-CoV-2–positive patients who died was 78.5 years. significantly higher usage of ARBs in hypertensive
patients with moderate COVID-19 disease than those with a severe and critical course of disease. There is no advantage to any group
of medications within RAAS inhibitors. There are no data regarding the association between RAAS inhibitors and the outcome.
Conclusion: There is a relation between COVID-19 and HTN and need more data to be clarify weather HTN is isolated risk
factor or as a reflection of ACEI or ARB. Age is associated with COVID19.